BRCA2

Common Name(s)

BRCA2

BRCA2 (breast cancer 2, early onset) is a specific gene found in a person’s DNA, or genetic code. Sometimes there are variations or mutations in a person’s genetic code. While some of these go unnoticed (harmless changes), others may put a person at risk for certain health problems. Harmful mutations in the BRCA2 gene (BRCA2 mutation) lead to an increased risk of certain cancers, especially breast cancer and ovarian cancer in women. On average, a woman with a BRCA2 mutation has up to a 40-85% lifetime risk of developing breast cancer and up to an 11-27% lifetime risk of developing ovarian cancer. The risk varies depending on the exact mutation, family history of cancer, reproductive history, and other genes which may modify the cancer risk. Men with a BRCA2 mutation may be at an increased risk to develop male breast and prostate cancer. Both men and women with a BRCA2 mutation may be at an increased risk to develop cancer of the pancreas or an aggressive form of skin cancer called melanoma. Individuals with a BRCA2 mutation require screening for these cancers more often. Some women may even decide to have prophylactic (risk reducing) surgical removal of the breasts (mastectomy) or ovaries (oophorectomy) before they have cancer, in order to prevent developing these cancers. Management and prevention options for individuals with a BRCA2 mutation are individualized based on other factors such as family history of cancer, personal preference, and other risk factors for cancer. To decide the best care plan, talk with your physician if you or a family member has a mutation in the BRCA2 gene. Talking with a genetic counselor or specialist may be helpful, as well as with other women and men who also have a BRCA2 mutation through support organizations. Genetic testing may be recommended if you have a family history of certain cancers or certain ethnic backgrounds. If you are concerned that you should be tested, speak with a genetic counselor.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "BRCA2" for support, advocacy or research.

Basser Research Center for BRCA

The Basser Research Center for BRCA provides education and support for individuals and families with BRCA1 and BRCA2 mutations. Our mission is to deliver cutting edge research in basic and clinical sciences to advance the care of individuals who carry BRCA mutations. The Basser Center is part of the Abramson Cancer Center at Penn Medicine.

Last Updated: 29 Oct 2014

View Details
Breast Cancer Options

Our mission is to educate breast cancer patients about effective treatment options, to advocate for and support informed patient choice and to promote public awareness regarding cancer risk reduction.

Last Updated: 13 Feb 2015

View Details
Center for Jewish Genetics

The Center is dedicated to gathering and disseminating knowledge about Jewish genetic disorders and hereditary cancers. Its mission is to educate and serve health care professionals, clergy and the Jewish community.

Last Updated: 26 Dec 2012

View Details
FORCE: Facing Our Risk of Cancer Empowered

FORCE is a national nonprofit dedicated to fighting hereditary breast and ovarian cancer. With 50 outreach groups throughout the U.S., and international affiliates, FORCE programs provide support, education, advocacy, awareness and research specific to hereditary cancers. Our programs serve anyone with a BRCA mutation or a family history of cancer. FORCE was founded on the principle that no one should have to face hereditary breast and ovarian cancer alone.

Last Updated: 5 May 2014

View Details
HIS Breast Cancer Awareness

An organization for information about Male Breast Cancer. We are here to inform, to educate, bring awareness, and to teach prevention regarding breast cancer in men and genetic testing. We are here to assist and inform once you have been diagnosed with breast cancer.

Last Updated: 1 Nov 2014

View Details
Sharsheret

Sharsheret is a national not-for-profit organization supporting young Jewish women and their families facing breast cancer. Our mission is to offer a community of support to women, of all Jewish backgrounds, diagnosed with breast cancer or at increased genetic risk, by fostering culturally-relevant individualized connections with networks of peers, health professionals, and related resources.

Last Updated: 5 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "BRCA2" for support, advocacy or research.

Basser Research Center for BRCA

The Basser Research Center for BRCA provides education and support for individuals and families with BRCA1 and BRCA2 mutations. Our mission is to deliver cutting edge research in basic and clinical sciences to advance the care of individuals who carry BRCA mutations. The Basser Center is part of the Abramson Cancer Center at Penn Medicine.

http://www.basser.org

Last Updated: 29 Oct 2014

View Details
Breast Cancer Options

Our mission is to educate breast cancer patients about effective treatment options, to advocate for and support informed patient choice and to promote public awareness regarding cancer risk reduction.

http://www.breastcanceroptions.org

Last Updated: 13 Feb 2015

View Details
Center for Jewish Genetics

The Center is dedicated to gathering and disseminating knowledge about Jewish genetic disorders and hereditary cancers. Its mission is to educate and serve health care professionals, clergy and the Jewish community.

http://www.jewishgenetics.org

Last Updated: 26 Dec 2012

View Details
FORCE: Facing Our Risk of Cancer Empowered

FORCE is a national nonprofit dedicated to fighting hereditary breast and ovarian cancer. With 50 outreach groups throughout the U.S., and international affiliates, FORCE programs provide support, education, advocacy, awareness and research specific to hereditary cancers. Our programs serve anyone with a BRCA mutation or a family history of cancer. FORCE was founded on the principle that no one should have to face hereditary breast and ovarian cancer alone.

http://www.facingourrisk.org

Last Updated: 5 May 2014

View Details
HIS Breast Cancer Awareness

An organization for information about Male Breast Cancer. We are here to inform, to educate, bring awareness, and to teach prevention regarding breast cancer in men and genetic testing. We are here to assist and inform once you have been diagnosed with breast cancer.

http://hisbreastcancer.org/

Last Updated: 1 Nov 2014

View Details
Sharsheret

Sharsheret is a national not-for-profit organization supporting young Jewish women and their families facing breast cancer. Our mission is to offer a community of support to women, of all Jewish backgrounds, diagnosed with breast cancer or at increased genetic risk, by fostering culturally-relevant individualized connections with networks of peers, health professionals, and related resources.

http://www.sharsheret.org

Last Updated: 5 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "BRCA2" returned 1002 free, full-text research articles on human participants. First 3 results:

BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
 

Author(s): Bárbara Alemar, Cleandra Gregório, Josef Herzog, Camila Matzenbacher Bittar, Cristina Brinckmann Oliveira Netto, Osvaldo Artigalas, Ida Vanessa D Schwartz, Jordy Coffa, Suzi Alves Camey, Jeffrey Weitzel, Patricia Ashton-Prolla

Journal:

 

Germline pathogenic variants in BRCA1 and BRCA2 (BRCA) are the main cause of Hereditary Breast and Ovarian Cancer syndrome (HBOC).

Last Updated: 31 Dec 1969

Go To URL
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
 

Author(s): Amit M Oza, Anna V Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A McNeish, Elizabeth M Swisher, Isabelle Ray-Coquard, Katherine Bell-McGuinn, Robert L Coleman, David M O'Malley, Alexandra Leary, Lee-May Chen, Diane Provencher, Ling Ma, James D Brenton, Gottfried E Konecny, Cesar M Castro, Heidi Giordano, Lara Maloney, Sandra Goble, Kevin K Lin, James Sun, Mitch Raponi, Lindsey Rolfe, Rebecca S Kristeleit

Journal: Gynecol. Oncol.. 2017 11;147(2):267-275.

 

An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC).

Last Updated: 31 Dec 1969

Go To URL
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
 

Author(s): Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu, Yuchao Jiang, Hao Chen, Nancy R Zhang, Nicole Hackman, Kurt D'Andrea, Robert Daber, Jennifer J D Morrissette, Nandita Mitra, Michael Feldman, Susan M Domchek, Katherine L Nathanson

Journal:

 

Complete loss of BRCA1 or BRCA2 function is associated with sensitivity to DNA damaging agents. However, not all BRCA1 and BRCA2 germline mutation-associated tumors respond. Herein we report analyses of 160 BRCA1 and BRCA2 germline mutation-associated breast and ovarian tumors. Retention ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "BRCA2" returned 60 free, full-text review articles on human participants. First 3 results:

Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
 

Author(s): Lilian Jara, Sebastian Morales, Tomas de Mayo, Patricio Gonzalez-Hormazabal, Valentina Carrasco, Raul Godoy

Journal:

 

Breast cancer (BC) is the most common malignancy among women worldwide. A major advance in the understanding of the genetic etiology of BC was the discovery of BRCA1 and BRCA2 (BRCA1/2) genes, which are considered high-penetrance BC genes. In non-carriers of BRCA1/2 mutations, disease ...

Last Updated: 31 Dec 1969

Go To URL
The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
 

Author(s): Javier Martinez-Useros, Jesus Garcia-Foncillas

Journal: Biomed Res Int. 2016 ;2016():1869304.

 

Pancreatic cancer is one of the deadliest cancers worldwide, and life expectancy after diagnosis is often short. Most pancreatic tumours appear sporadically and have been highly related to habits such as cigarette smoking, high alcohol intake, high carbohydrate, and sugar consumption. ...

Last Updated: 31 Dec 1969

Go To URL
Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.
 

Author(s): Carlos Andrés Ossa, Diana Torres

Journal: Oncologist. 2016 Jul;21(7):832-9.

 

Numerous epidemiological factors affect the probability of developing breast or ovarian cancer, but no predictor is as determinant as inheriting a mutation in BRCA1 or BRCA2. The concept of the founder effect explains the reduced genetic variability in some populations, according ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Prospective Cohort Study of Variant Carriers With BRCA1 or BRCA2
 

Status: Recruiting

Condition Summary: BRCA1 and/or BRCA2 Variant Carriers; Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma

 

Last Updated: 22 Nov 2017

Go to URL
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
 

Status: Recruiting

Condition Summary: BRCA1 Gene Mutation; BRCA2 Gene Mutation; Ovarian Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma

 

Last Updated: 10 Jul 2017

Go to URL
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
 

Status: Recruiting

Condition Summary: Prostate Cancer in BRCA1 and BRCA2 Carriers

 

Last Updated: 12 Sep 2017

Go to URL